These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

775 related items for PubMed ID: 17016557

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.
    Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM.
    Cancer Res; 2007 Aug 01; 67(15):7358-67. PubMed ID: 17671206
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
    Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM.
    Am J Pathol; 2004 Jul 01; 165(1):35-52. PubMed ID: 15215160
    [Abstract] [Full Text] [Related]

  • 4. Imaging tumor angiogenesis.
    Red-Horse K, Ferrara N.
    J Clin Invest; 2006 Oct 01; 116(10):2585-7. PubMed ID: 17016553
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
    Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM.
    Am J Physiol Heart Circ Physiol; 2006 Feb 01; 290(2):H547-59. PubMed ID: 16172161
    [Abstract] [Full Text] [Related]

  • 7. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.
    Cancer Res; 2009 May 15; 69(10):4527-36. PubMed ID: 19401451
    [Abstract] [Full Text] [Related]

  • 8. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM, Paoni SF.
    Cancer Res; 2007 Oct 15; 67(20):9921-8. PubMed ID: 17942924
    [Abstract] [Full Text] [Related]

  • 9. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    Pernasetti F, Nickel J, Clark D, Baeuerle PA, Van Epps D, Freimark B.
    Int J Oncol; 2006 Dec 15; 29(6):1371-9. PubMed ID: 17088974
    [Abstract] [Full Text] [Related]

  • 10. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
    You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM.
    Cancer Res; 2011 Jul 15; 71(14):4758-68. PubMed ID: 21613405
    [Abstract] [Full Text] [Related]

  • 11. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.
    Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM.
    Am J Pathol; 2002 Mar 15; 160(3):985-1000. PubMed ID: 11891196
    [Abstract] [Full Text] [Related]

  • 12. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
    Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L.
    Angiogenesis; 2004 Mar 15; 7(3):225-33. PubMed ID: 15609077
    [Abstract] [Full Text] [Related]

  • 13. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA.
    Nature; 2008 Dec 11; 456(7223):809-13. PubMed ID: 18997771
    [Abstract] [Full Text] [Related]

  • 14. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
    Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT.
    Br J Cancer; 2015 Feb 03; 112(3):495-503. PubMed ID: 25562438
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth.
    Mundel TM, Yliniemi AM, Maeshima Y, Sugimoto H, Kieran M, Kalluri R.
    Int J Cancer; 2008 Apr 15; 122(8):1738-44. PubMed ID: 18074349
    [Abstract] [Full Text] [Related]

  • 17. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
    Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK.
    Cancer Cell; 2004 Dec 15; 6(6):553-63. PubMed ID: 15607960
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
    Franco M, Pàez-Ribes M, Cortez E, Casanovas O, Pietras K.
    Horm Metab Res; 2011 Nov 15; 43(12):884-9. PubMed ID: 21960459
    [Abstract] [Full Text] [Related]

  • 20. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D.
    J Clin Invest; 2003 May 15; 111(9):1287-95. PubMed ID: 12727920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.